10 results match your criteria: "Statistics and Clinical Audit[Affiliation]"
J Heart Lung Transplant
June 2018
Mater Misericordiae University Hospital, Dublin, Ireland.
The second annual IMACS registry report includes over 14, 000 patients from 35 countries. Survival, adverse events, and an updated risk model is presented. Continuous flow pumps continue to dominate the world's experience.
View Article and Find Full Text PDFJ Heart Lung Transplant
April 2016
Statistics and Clinical Audit, National Health Service, Blood and Transplant, Bristol, United Kingdom.
The first annual report of the International Society for Heart and Lung Transplantation (ISHLT) Mechanically Assisted Circulatory Support (IMACS) registry provides global data on 5,942 patients from 31 countries. This initial report focuses on patient demographics, survival, device types, adverse events, competing outcomes, and a risk factor analysis.
View Article and Find Full Text PDFBone Marrow Transplant
March 2015
1] Bone Marrow Transplant Unit, Bristol Royal Hospital for Children, Bristol, UK [2] School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Microsatellite analyses show that self-reported ethnicity often correlates poorly with true genetic ancestry. As unknown ancestral differences could potentially have an impact on transplant outcome, we developed an average allele length discrepancy (AALD) score to assess allele length discrepancy between donor/recipient (D/R) using microsatellites analysed routinely in post-transplant chimeric assessment. This was then compared with outcome in a homogeneously treated cohort of pediatric patients undergoing high-resolution sibling or matched unrelated donor transplantation for acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFCytometry B Clin Cytom
January 2015
Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, United Kingdom.
Background: The eosin-5'-maleimide (EMA) Binding test measures reduced mean channel fluorescence (MCF) reading of EMA-labeled red cells (EMA-RBCs) from patients with hereditary spherocytosis (HS). Reporting test results can be either in the actual MCF reading or as a ratio by normalization of the test MCF result to the mean MCF value of six normal controls. The latter format has potential for universal reporting.
View Article and Find Full Text PDFCytometry B Clin Cytom
September 2014
Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, UK.
Background: The EMA Binding test measures reduced mean channel fluorescence (MCF) reading of EMA-labeled red cells (EMA-RBCs) from patients with hereditary spherocytosis (HS). Reporting test results can be either in the actual MCF reading or as a ratio by normalization of the test MCF result to the mean MCF value of 6 normal controls. The latter format has potential for universal reporting.
View Article and Find Full Text PDFTransplantation
January 2013
Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, UK.
Background: The pool of suitable donors and listed recipients for intestinal transplantation is small, resulting in difficulties in donor-to-recipient matching and significant mortality on the waiting list. This study aims to help define the pool of potential donors for intestinal transplantation and propose methods for an increased utilization of donor bowels in the United Kingdom.
Methods: Data on bowel offering from 657 donors after brain stem death (DBD) and on 46 patients on the active intestinal transplant list over 12 months from 14 April 2011 were obtained from the UK Transplant Registry.
Liver Transpl
May 2012
Statistics and Clinical Audit, National Health Service Blood and Transplant, Bristol, United Kingdom.
The limited availability of livers donated by deceased donors for transplantation means that not everyone who might benefit from the procedure can receive a graft, so any selection and allocation system must have clearly defined goals. The United Kingdom, in common with many other countries, has adopted a minimum benefit criterion of a greater than 50% probability of survival 5 years after transplantation. We investigated the impact of changing this minimum benefit criterion on a case mix of listed patients.
View Article and Find Full Text PDFTransfusion
June 2011
Bristol Institute for Transfusion Sciences and Division of Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, UK.
Background: Most hematopoietic progenitor cell (HPC) products are infused or processed shortly after collection, but in some cases this may be delayed for up to 48 hours. A number of variables such as temperature and cell concentration are of critical importance for the integrity of HPCs during this time.
Study Design And Methods: We evaluated critical variables using cord blood HPC units that were divided equally and stored at 4 °C versus room temperature (RT) for up to 96 hours.
Am J Transplant
August 2010
Statistics and Clinical Audit, NHS Blood and Transplant, Bristol BS34 8RR, UK.
An increased incidence of malignancy is an established complication of organ transplantation and the associated immunosuppression. In this study on cancer incidence in solid organ transplant recipients in Britain, we describe the incidence of de novo cancers in the allograft recipient, and compare these incidences following the transplantation of different organs. Data in the UK Transplant Registry held by NHS Blood and Transplant (NHSBT) were linked with data made available by the cancer registries in England, Scotland and Wales.
View Article and Find Full Text PDFTransplantation
October 2009
Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, United Kingdom.
Mandatory continuous monitoring of early transplant outcome with centralized oversight was introduced in 2004 for all 23 UK adult kidney transplant units. Risk-adjusted cumulative sum charts are used to assess 30-day graft and patient survival against past performance for each center, and change in transplant center performance is assessed by tabular cumulative sum charts. The monitoring scheme has performed as predicted from simulations used to establish outcome thresholds and has been validated by comparison with 1- and 5-year outcome data for all UK transplant centers.
View Article and Find Full Text PDF